Ireland CDMO Directory & Sourcing Engine 2026

Aenova Competence Center for spray drying and modified release pellets, trading on-site as Temmler Ireland Ltd. Over 50 years of site experience (since 1972) producing oral solids and inhalation powders.

Opened a £65M, 100,000 sq ft commercial manufacturing facility in March 2025 for oral dose and potent drug products, alongside a separate 28,000 sq ft GMP peptide API synthesis plant (completed 2024) supporting growing demand for peptide therapeutics.

APC (Applied Process Company) is a Dublin-based pharmaceutical process development organization, spun out of UCD in 2011 by Dr. Mark Barrett and Prof. Brian Glennon. It focuses on process development and scale-up rather than commercial manufacturing itself — GMP manufacturing is handled by sister company VLE Therapeutics as part of their joint 'Medicine Accelerator' campus. A €100M expansion announced in 2024 is adding 300 R&D jobs and a new 130,000 sq ft building.

Founded in Ireland in 1960, Bimeda is a global animal health company whose Tallaght, Dublin facility offers contract and toll manufacturing plus private-label production for distributors and international companies in liquid veterinary dosage forms — oral drenches, nutritional liquids, ectoparasiticides and disinfectants — alongside its own branded veterinary product lines.

Acquired by Cambrex in 2022, this facility features 40+ walk-in ICH stability storage chambers and cryogenic freezers down to -80°C.

Ireland's largest indigenous manufacturer of generic pharmaceuticals for both human and veterinary use. Founded in 1985 by Michael H. Burke in Loughrea, Co. Galway, the company grew over almost four decades into a group holding 1,200+ human and 3,000+ animal health licenses, the largest veterinary licence portfolio of any animal health company in the EU, exporting to 90-100 countries worldwide. Operations run across two divisions: Human Health, manufacturing generic prescription and OTC medicines, and Animal Health, established in the UK market since 1991 with 50+ active brands across trade, veterinary and pet retail channels. The Loughrea campus itself has grown with the business, with a 2021 conversion adding a further 35,000 sq ft manufacturing facility at Ballinasloe, alongside the original site's multiple production buildings and R&D laboratories. Beyond its own generics portfolio, Chanelle offers contract development, manufacturing and packaging services to other human and animal health companies, backed by HPRA licensing and an FDA-approved manufacturing line (Spot On, operational since September 2019). In February 2024, founder Michael H. Burke sold the company to UK private equity firm Exponent for an estimated €300 million and retired. Angelo Gatto was appointed CEO that August, bringing 25 years of pharmaceutical leadership experience from Johnson & Johnson, Pfizer, Aenova Group and Adragos Pharma to lead the next phase of growth.

Specializes in high-potency oral solid dose medicines for oncology and rare diseases. Produces 520M dosage units annually across 60 countries, targeting 1B units/yr by 2027.

First Irish CDMO licensed by HPRA for cell and gene therapy (ATMP) manufacturing, confirmed by independent press coverage (Irish Times, Feb 2024). Provides drug substance, drug product formulation, and cryogenic cold-chain logistics.

Hovione describes itself as a global leader in spray drying and particle engineering for inhalable therapies and low bioavailability oral drugs. Operates 24/7 continuous production with GEA and Büchi platforms on the former Pfizer Lipitor API site, acquired in 2008/2009.

Existing 45,000 sq ft site paired with new 82,000 sq ft facility dedicated to final assembly, labeling, and packaging of biologic injectables, pre-filled syringes, and autoinjectors.

Founded in 1976 by Michael Costello to serve Ireland's renal/dialysis care market, Pinewood Healthcare has been owned by India's Wockhardt Group since a 2006 acquisition (~$150M). Manufactures oral liquids, suspensions, powders, creams and ointments — both its own generic portfolio (200+ licensed formulations across 30+ countries) and third-party contract manufacturing.

Acquired from Novartis in 2022, this 111-acre Ringaskiddy campus (operating since 1994) is one of Sterling Pharma Solutions' largest global API manufacturing sites, led by EVP & Site Head Maeve Byrne. Specializes in peptide manufacturing and large-scale chromatography alongside general API development and manufacturing.

Acquired from GSK in 2019 for €90M, this manufacturing site traces its roots to 1975 and doubled its lab and analytical capacity in a 2023 expansion, serving complex small-molecule API manufacturing for global pharmaceutical customers.

Founded in 2006, TopChem is a GMP manufacturer of niche, low-volume active pharmaceutical ingredients and excipients that are difficult for customers to source elsewhere. A new Collooney, Co. Sligo facility came online in 2024, roughly tripling total production capacity with a dedicated new R&D centre. Sole API supplier for the only FDA-approved Bretylium Tosylate injection on the US market.

Ireland's first WuXi Biologics manufacturing site (announced 2018, €325M initial investment), featuring 48,000L fed-batch bioreactor capacity using single-use and continuous bioprocessing technology. Distinct from the adjacent WuXi Vaccines facility on the same campus, which was sold to Merck/MSD in 2025 — this biologics drug substance/drug product plant remains WuXi-operated and gained EMA commercial manufacturing approval in August 2025.